1-20 of 42 results for subject:"Hay fever"
Librarians' tools
- Search time
- 0.287 seconds
- Solr query time
- 0.004 seconds
- Search query
- subject:"Hay fever"
- We searched for
- subject_t:"Hay fever" OR subject_t:"Allergic rhinitis" OR subject_ses:290522
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with relevant professional bodies on the (a) clinical management and (b) treatment of hay fever.
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with relevant professional bodies on the (a) clinical management and (b) treatment of hay fever.
No recent discussions have taken place on the clinical management and treatment of hay fever specifically, however, as part of the Expert Advisory Group for Allergy, Department policy officials meet regularly with the National Allergy Strategy Group, which includes the professional body, the British Society for Allergy and Clinical Immunology. The most recent meeting was in April 2025.
The Expert Advisory Group for Allergy, which was established in 2023, is co-chaired by the Department and the National Allergy Strategy Group, and brings stakeholders together to inform policymaking and to identify key priorities in relation to the holistic care of people with allergies, including those with hay fever. The National Allergy Strategy Group is developing the UK National Allergy Strategy 2025-2035. The Department will carefully consider, and respond to, recommendations in the strategy when we receive it later this year.
To ask His Majesty's Government, in relation to the use of montelukast in the UK, what assessment they have made of the US Food and Drug Administration's issuing a “black box warning” in March 2020 about serious mental health side effects of the drug and restricting its use for allergic rhinitis.
To ask His Majesty's Government, in relation to the use of montelukast in the UK, what assessment they have made of the US Food and Drug Administration's issuing a “black box warning” in March 2020 about serious mental health side effects of the drug and restricting its use for allergic rhinitis.
Montelukast remains a safe and effective medicine in the treatment of asthma. Montelukast is indicated for use in the United Kingdom as an add on treatment for asthma patients who are inadequately controlled on inhaled corticosteroid treatment, and can be prescribed for the symptomatic relief of seasonal allergic rhinitis in patients with asthma. There is no licensed indication in the UK for the treatment of allergic rhinitis alone.
Neuropsychiatric effects such as depression have been included in the UK product information for montelukast since 2007. This has been subsequently updated with additional terms based on emerging evidence. This includes the most recent update in 2019, which more fully described the neuropsychiatric effects. In order to remind prescribers of the risk of neuropsychiatric effects with montelukast, a Drug Safety Update article was published by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2019, to accompany the updated warnings.
Following a growing number of Yellow Card reports and queries from patients and caregivers, raising concerns about a potential ongoing lack of awareness of the risk of the neuropsychiatric effects with montelukast, the MHRA is conducting a further review of the current data.
As part of our review, we are evaluating all available evidence, including Yellow Card reports and queries received by the MHRA, literature publications, international regulatory changes, including those made by the United States’ Food and Drug Administration, and are listening to and learning from patients’ experiences. The MHRA has sought advice from our independent expert groups including paediatricians, specialists in mental and respiratory health, as well as experts in medicines safety.
We are considering all relevant regulatory actions that would provide the most effective way of increasing awareness to healthcare professionals, patients, and their caregivers. The MHRA is finalising the review process and will communicate on any further measures to minimise the risk, upon completion of our review.
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the number of people who are on prescription medication for hayfever.
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the number of people who are on prescription medication for hayfever.
Information is held on prescriptions for individual medicines, but not for the clinical reason for that prescription. Therefore, the information requested on the number of people who are on prescription medication for treatment of hay fever, is not held centrally.
While information is collected on the number of items dispensed for medications licensed for treatment of hay fever, some patients may be prescribed these medicines for conditions other than hay fever and some patients may be prescribed medication licensed for other indications to treat their hay fever.
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of people who are affected by hayfever each year.
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of people who are affected by hayfever each year.
No specific estimate has been made.
To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of people who have hay fever in the last five years.
To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of people who have hay fever in the last five years.
This data is not held.
To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 6 April (HL2662), what assessment they have made of the particular vulnerability of hay fever and asthma sufferers to COVID-19.
To ask Her Majesty's Government, further to the Written Answer by Lord Bethell on 6 April (HL2662), what assessment they have made of the particular vulnerability of hay fever and asthma sufferers to COVID-19.
At present there is insufficient evidence to determine whether there is any particular vulnerability of hay fever and asthma sufferers to COVID-19.
The British Thoracic Society’s Advice for Healthcare Professionals Treating People with Asthma (adults) in relation to COVID-19 and the National Institute for Health and Care Excellence’s COVID-19 rapid guideline: severe asthma, recommend that patients should continue taking their regular medications in line with their personalised asthma action plan. Some patients with severe asthma have been identified as being potentially extremely vulnerable to COVID-19 and been placed in the shielding group.
With regards to hay fever, the Global Initiative for Asthma and the Allergic Rhinitis and its Impact on Asthma organisation recommend that people with allergic rhinitis should continue to take their nasal corticosteroids, as prescribed by their healthcare professional.
To ask Her Majesty's Government, further to reports that the projected peak of COVID-19 will coincide with the hay fever season, what advice they are giving to hay fever sufferers
To ask Her Majesty's Government, further to reports that the projected peak of COVID-19 will coincide with the hay fever season, what advice they are giving to hay fever sufferers
Individuals who suffer from hay fever should refer to the National Health Service and Public Health England guidance regarding the most common symptoms of COVID-19 and what to do if these are present. A copy of the online guidance is attached.
No specific guidance is planned for hay fever sufferers in relation to COVID-19, but NHS guidance on hay fever is attached.
To ask the Secretary of State for Health, how many people (a) have been diagnosed and (b) are being treated for hay fever aged (i) 10 to 16, (ii) 16 to 30, (iii) 30 to 80 and (iv) over 60 years in the last 12 months.
To ask the Secretary of State for Health, how many people (a) have been diagnosed and (b) are being treated for hay fever aged (i) 10 to 16, (ii) 16 to 30, (iii) 30 to 80 and (iv) over 60 years in the last 12 months.
This information is not collected.
To ask the Secretary of State for Health, what recent discussions he has had with the Royal Colleges on the treatment of hayfever.
To ask the Secretary of State for Health, what recent discussions he has had with the Royal Colleges on the treatment of hayfever.
No recent discussions have taken place between the Ministers of the Department and the Royal Colleges on the treatment of hay fever.
To ask the Secretary of State for Health, what recent discussions he has had with the Royal Colleges about links between hayfever and dementia.
To ask the Secretary of State for Health, what recent discussions he has had with the Royal Colleges about links between hayfever and dementia.
Improving the treatment and care of people with dementia, reducing the incidence of dementia and improving dementia research, is a key priority for the Government.
My Rt. hon. Friend the Secretary of State has had and continues to have numerous meetings with various stakeholders including Royal Colleges in which numerous topics are discussed.
To ask the Secretary of State for Health what advice his Department issues to those with hay fever; how much his Department spent on provision of such advice in the latest period for which figures are available; what mechanisms his Department uses to disseminate such advice to members of the...
To ask the Secretary of State for Health what advice his Department issues to those with hay fever; how much his Department spent on provision of such advice in the latest period for which figures are available; what mechanisms his Department uses to disseminate such advice to members of the...
To ask the Secretary of State for Health what recent (a) discussions he has had with and (b) representations he has received from the British Medical Association on the treatment of patients suffering with hay fever; and if he will make a statement.
To ask the Secretary of State for Health what recent (a) discussions he has had with and (b) representations he has received from the British Medical Association on the treatment of patients suffering with hay fever; and if he will make a statement.
To ask the Secretary of State for Health what guidance his Department (a) has issued and (b) plans to issue to (i) GPs and (ii) hospitals on the treatment of patients suffering with hay fever; and if he will make a statement.
To ask the Secretary of State for Health what guidance his Department (a) has issued and (b) plans to issue to (i) GPs and (ii) hospitals on the treatment of patients suffering with hay fever; and if he will make a statement.
To ask the Secretary of State for Health what estimate he has made of the number of (a) males and (b) females with hay fever in each age group in each of the last five years; and if he will make a statement.
To ask the Secretary of State for Health what estimate he has made of the number of (a) males and (b) females with hay fever in each age group in each of the last five years; and if he will make a statement.
| Proportion of patients consulting a GP for allergic rhinitis at some point during 2004 (rates per 10,000) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age standardised rate (95% CI) | All ages | <1 | 1-4 | 5-14 | 15-24 | 25-44 | 45-64 | 65-74 | 75+ | |
| Male | 152 (147-158) | 152 | 5 | 112 | 308 | 241 | 143 | 86 | 84 | 77 |
| Female | 171 (165-177) | 173 | 0 | 73 | 224 | 305 | 214 | 121 | 89 | 70 |
To ask the Secretary of State for Health how many (a) males and (b) females in each (i) age group and (ii) health authority area were prescribed medication for the relief of hay fever in each of the last five years for which figures are available.
To ask the Secretary of State for Health how many (a) males and (b) females in each (i) age group and (ii) health authority area were prescribed medication for the relief of hay fever in each of the last five years for which figures are available.
| Prescription items for antihistamines prescribed in England and dispensed in the community in the UK, by SHA, July 2006-10 | |||||
|---|---|---|---|---|---|
| Thousand | |||||
| SHA | July-December 2006¹ | 2007 | 2008 | 2009 | 2010 |
| East Midlands | 377.3 | 849.4 | 904.4 | 973.9 | 1,037.5 |
| East of England | 475.8 | 1,047.7 | 1,103.3 | 1,186.9 | 1,250.2 |
| London | 553.6 | 1,322.9 | 1,375.3 | 1,489.8 | 1,569.7 |
| North East | 236.3 | 504.7 | 538.9 | 578.0 | 615.3 |
| North West | 651.2 | 1,386.8 | 1,453.3 | 1,537.8 | 1,614.2 |
| South Central | 292.1 | 661.1 | 683.0 | 722.4 | 751.3 |
| South East Coast | 304.8 | 674.6 | 703.7 | 745.6 | 783.2 |
| South West | 371.5 | 822.7 | 868.6 | 920.6 | 971.8 |
| West Midlands | 444.7 | 991.7 | 1,037.1 | 1,107.0 | 1,165.2 |
| Yorkshire and the Humber | 483.4 | 1,036.4 | 1,086.6 | 1,168.7 | 1,234.5 |
| Unidentified prescribing² | 5.4 | 5.7 | 10.1 | 6.2 | 13.3 |
| Total³, 4 | 9,088.6 | 9,303.6 | 9,764.3 | 10,436.9 | 11,006.2 |
| Prescription items for topical nasal steroids prescribed in England and dispensed in the community in the UK, by SHA, July 2006-10 | |||||
|---|---|---|---|---|---|
| Thousand | |||||
| SHA | July-December 2006¹ | 2007 | 2008 | 2009 | 2010 |
| East Midlands | 204.5 | 463.4 | 500.1 | 528.2 | 559.1 |
| East of England | 264.1 | 591.4 | 631.7 | 664.3 | 700.2 |
| London | 260.2 | 634.6 | 673.3 | 716.7 | 751.3 |
| North East | 109.3 | 237.3 | 254.2 | 266.3 | 281.6 |
| North West | 314.9 | 696.8 | 738.4 | 786.2 | 824,7 |
| South Central | 177.6 | 400.8 | 424.7 | 443.1 | 464.0 |
| South East Coast | 178.7 | 400.0 | 419.0 | 438.2 | 457.4 |
| South West | 225.8 | 505.0 | 536.1 | 560.7 | 589.3 |
| West Midlands | 232.6 | 527.7 | 564.0 | 598.6 | 633.1 |
| Yorkshire and the Humber | 221.2 | 488.9 | 524.3 | 558.6 | 587.2 |
| Unidentified prescribing² | 0.9 | 1.9 | 3.9 | 2.0 | 4.2 |
| Total³, 4 | 4,759.7 | 4,947.8 | 5,269.7 | 5,563.0 | 5,852.1 |
| Prescription items for other anti-inflammatory preparations for eye problems prescribed in England and dispensed in the community in the UK, by SHA, July 2006-10 | |||||
|---|---|---|---|---|---|
| Thousand | |||||
| SHA | July-December 2006¹ | 2007 | 2008 | 2009 | 2010 |
| East Midlands | 51.1 | 132.9 | 144.3 | 149.2 | 148.7 |
| East of England | 62.9 | 160.4 | 169.7 | 174.2 | 171.3 |
| London | 107.7 | 301.6 | 325.8 | 340.4 | 341.2 |
| North East | 28.0 | 62.8 | 67.1 | 69.6 | 69.9 |
| North West | 82.5 | 196.5 | 208.2 | 214.9 | 209.4 |
| South Central | 39.1 | 105.2 | 111.6 | 114.1 | 113.1 |
| South East Coast | 38.8 | 98.7 | 104.5 | 107.2 | 104.8 |
| South West | 47.0 | 122.3 | 129.7 | 133.1 | 130.2 |
| West Midlands | 68.6 | 174.0 | 187.4 | 194.4 | 194.0 |
| Yorkshire and the Humber | 59.7 | 144.5 | 154.5 | 163.2 | 159.8 |
| Unidentified prescribing² | 0.5 | 0.8 | 1.8 | 1.0 | 2.0 |
| Total³, 4 | 1,531.3 | 1,499.7 | 1,604.8 | 1,661.1 | 1,644.4 |
| ¹ SHAs were reorganised in July 2006, comparable data are not available for January-June 2006 | |||||
| ² 'Unidentified prescribing' is prescribing which cannot be attributed to an SHA | |||||
| ³ Figures may not sum due to rounding | |||||
| 4 England total for 2006 relates to full year January-December dispensing | |||||
| Source: | |||||
| Prescribing Analysis and Cost Tool (PACT) system |
To ask the Secretary of State for Health what research has been (a) commissioned and (b) evaluated by his Department on the number of (i) males and (ii) females diagnosed with hay fever; and if he will make a statement.
To ask the Secretary of State for Health what research has been (a) commissioned and (b) evaluated by his Department on the number of (i) males and (ii) females diagnosed with hay fever; and if he will make a statement.
To ask the Secretary of State for Children, Schools and Families what research has been (a) commissioned and (b) evaluated by his Department on the number of pupils affected by hay fever at (i) primary and (ii) secondary schools; and if he will make a statement.
To ask the Secretary of State for Children, Schools and Families what research has been (a) commissioned and (b) evaluated by his Department on the number of pupils affected by hay fever at (i) primary and (ii) secondary schools; and if he will make a statement.
To ask the Secretary of State for Children, Schools and Families what work his Department (a) has undertaken and (b) plans to undertake on provision of clinical care to children with hay fever in schools; and what measures are in place to ensure that such children receive appropriate medication during...
To ask the Secretary of State for Children, Schools and Families what work his Department (a) has undertaken and (b) plans to undertake on provision of clinical care to children with hay fever in schools; and what measures are in place to ensure that such children receive appropriate medication during...
To ask the Secretary of State for Education and Skills what assessment he has made of the merits of changing the timings of (a) GCSE and (b) A-level examinations, with particular reference to the effect on seasonal allergic rhinitis sufferers.
To ask the Secretary of State for Education and Skills what assessment he has made of the merits of changing the timings of (a) GCSE and (b) A-level examinations, with particular reference to the effect on seasonal allergic rhinitis sufferers.